18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer
This trial is active, not recruiting.
|Treatment||18f-fluordeoxyglucose positron emission tomography/ computed tomography|
|Collaborator||University of Copenhagen|
|Start date||July 2009|
|End date||March 2013|
|Trial size||66 participants|
|Trial identifier||NCT01636674, SJ-82|
The investigators are investigating the usefulness of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography (18F-FDG PET/CT) for staging and follow-up of colon cancer. Furthermore, the investigators combine 18F-FDG PET findings with clinical and histopathological features, circulating tumor cell (CTC) analyses, tumor gene expression and measurements of circulating cancer biomarkers sUPAR, TIMP-1 and CEA in order to predict tumor recurrence.
The investigators hypothesis: The combination of functional imaging by 18F-FDG PET/CT and pre-existing and evolving molecular biomarkers will optimize tumor characterization, staging of disease and early detection of recurrence.
|Intervention model||single group assignment|
time to recurrence
Male or female participants at least 18 years old.
- clinical or histological diagnosis of malignant clonic neoplasm (distance of more than 15 cm from anal ring)
- 18 years of age or older
- written informed consent
- known malignant disease other than colon cancer
- known metastatic disease
- impairment of renal function
- allergy to CT contrast agents
- body weight of more than 150 kg
|Official title||Value of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography and Molecular Tumor Characterisation in Preoperative Staging og Postoperative Control of Colon Cancer|
|Principal investigator||Bodil E Engelmann, MD|
Call for more information